'EXPECTED' ESTIMATES FOR PARENTERAL B12
The prevalence of pernicious anaemia was established by Scott (1960) . We have assumed that there was no significant change in prevalence between his survey and 1966. We also required an estimate of incidence as the dosage for newly diagnosed cases differs from that for maintenance. For this we have relied on the number of new cases diagnosed in Cardiff hospitals among people who lived in Cardiff in 1960 and 1965 . These figures may underestimate the annual incidence, but as a considerable error in incidence would cause only a very small change in expected requirements we have not pursued the matter further. For dosage we have felt forced to use two standards-an 'ideal' and a 'reasonable'. The ideal is based on reputable publications prior to 1966, but as the estimates of necessary dosage were falling at that time it was unreasonable to expect all doctors to adjust their maintenance doses quickly so we have calculated the results for what was previously the accepted dosages. The figures are given in Tables IA, B , C, and D which combine these figures with Scott's prevalence figures, corrected for incidence, to give 'expected' prescribed dosage.
We were, of course, aware that B12 could correctly be prescribed for other megaloblastic anaemia or potential megaloblastic anaemia conditions. We were unfortunately unable to establish their prevalence or incidence with any accuracy so we have delayed discussion of this point to a later section. Table IIA . While we were doing this work in this country Pedersen and Mosbech (1969) published a very similar analysis for Denmark (Table III) . The two countries seem to be prescribing equally badly-or equally well.
ESTIMATES OF 'EXPECTED AND OBSERVED' COSTS
The costs for the general practice prescriptions were obtained from the Department, and the hospital costs were completed from the details supplied by the various Boards, using 1966 prices for each strength. For estimating expected costs we assumed that new cases occurred in hospital and that maintenance doses were given at home. We have estimated the drug cost of the private sphere by the difference between the total as supplied by manufacturers and the combined total for hospitals and general practice, and paid for at the same rate as in general practice. It is unfortunately impossible to check this figure but we do not believe the error to be large. All these results are summarized in Table  IV . The actual costs would, of course, be very much larger if the cost of nurses, syringes, etc. were 
